Clinical Research Services Turku CRST Oy

The site advances diagnostic imaging and biomarker platforms to support early detection and monitoring across several disease areas.

• Use of advanced PET imaging for neurodegenerative conditions
• Development of blood‑based biomarkers for cognitive decline
• Optimisation of MRI protocols in multiple sclerosis trials

Clinical Research Services Turku CRST Oy leverages these tools to improve trial precision and patient outcomes.

Research at the Turku centre focuses on disorders of the gastrointestinal tract, especially celiac disease and related gluten‑sensitivity conditions.

• Evaluation of novel agents that reduce celiac disease symptoms
• Assessment of intestinal mucosal healing after gluten challenge
• Studies on dietary adherence and quality of life in gluten‑free diets

The programme aims to provide better therapeutic options for patients struggling with persistent gastrointestinal issues.

The Turku site conducts trials targeting autoimmune conditions, including psoriasis and multiple sclerosis.

• Dose‑finding studies for new biologics in mild‑to‑moderate psoriasis
• Evaluation of subcutaneous antibodies for relapsing multiple sclerosis
• Investigation of immune‑modulating pathways in inflammatory skin disorders

These efforts support the development of treatments that modulate the immune response while preserving safety.

Oncology research at the facility centers on advanced prostate cancer, specifically metastatic castration‑resistant prostate cancer.

• Testing of investigational radiopharmaceuticals for tumor targeting
• Combination therapy safety and efficacy assessments
• Biomarker‑driven patient selection strategies

The goal is to expand therapeutic options for patients with aggressive disease forms.

Trials address a range of neurological disorders, from Alzheimer's disease to Parkinson's disease and narcolepsy.

• Interventions aimed at slowing cognitive decline in early Alzheimer’s
• Neuroprotective agents for Parkinson’s disease symptom management
• Safety and efficacy studies of novel treatments for narcolepsy

Clinical Research Services Turku CRST Oy seeks to improve functional outcomes for patients living with neuro‑degenerative conditions.

Focused research on dermatological conditions highlights psoriasis as a key indication.

• Phase studies to determine optimal dosing for new topical or systemic agents
• Patient‑reported outcome measures evaluating skin‑related quality of life
• Long‑term safety monitoring of emerging immunotherapies

The program aims to bring effective and well‑tolerated treatments to individuals affected by chronic skin disease.

Mental health research includes investigations of major depressive disorder, schizophrenia and related cognitive impairments.

• Adjunctive therapies for depression with inadequate response to standard antidepressants
• Cognitive function assessments in patients with schizophrenia
• Exploration of kappa‑opioid receptor antagonists for mood improvement

These studies aim to enhance therapeutic options and improve daily functioning for people living with mental illness.